New phase 3 data show meaningful improvement in antibody-negative myasthenia gravis, for which treatment options are limited ...

Takenobu Y, Kikuchi T, Ishikawa D, et al. Rozanolixizumab as rescue therapy in triple seronegative refractory generalized ...

The ongoing EPIC clinical trial is the first randomized head-to-head comparison of two neonatal Fc receptor (FcRn)-targeting ...

Early data from the ADAPT JR trial suggest efgartigimod may benefit adolescents with generalized myasthenia gravis, a rare condition with few effective treatment options.

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the enrollment of the first patient in the new PPD(TM) CorEvitas(TM) Myasthenia Gravis (MG) Registry. This ...

Experts discuss personalized myasthenia gravis treatment, emphasizing patient education and engagement for optimal care and advocacy in managing this variable disease. Personalizing treatment for ...

Johnson & Johnson (NYSE: JNJ) announced plans to launch the first-ever head-to-head study comparing its FcRn blocker IMAAVY™ (nipocalimab-aahu) with efgartigimod in adults living with generalized ...

SAN FRANCISCO -- Investigational gefurulimab met its primary efficacy endpoint in adults with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (MG), topline data from ...

Treatment with cemdisiran was associated with a statistically significant improvement in MG-ADL total score compared with placebo. Topline results were announced from a phase 3 trial evaluating ...

Provided by the Academy for Continued Healthcare Learning (ACHL). Discuss the clinical burden often associated with generalized myasthenia gravis (gMG) Appraise the latest clinical trial data ...

Despite the recent approval of targeted biologics that can significantly improve quality of life, Canadians living with Myasthenia Gravis continue to face unjust policy barriers.